Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
Your Article Summary
See Latest ArticlesHigh-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: A prospective open study
International Journal of Rheumatic Diseases, 08/19/09
Wanchu A et al. – Study shows that high-dose prednisolone with pulse cyclophosphamide (CYC) can either improve or stabilize lung functions in patients with severe systemic sclerosis (SSc) lung disease irrespective of presence of ground glass appearance on high-resolution computed tomography (HRCT).
Methods- A study in North Indian tertiary institute to assess the efficacy of intermittent pulse CYC and high-dose prednisolone in SSc-related interstitial lung disease (ILD)
- Consecutive pts with SSc and ILD, diagnosed on spirometry, carbon monoxide diffusing capacity (DLCO) and (HRCT) scan were treated
- Pulmonary function tests were carried out at baseline and after 6 mo
- Pts received oral prednisolone 1 mg/kg body weight initially, with tapering to a dose of 7.5 mg/d
- Monthly CYC pulses were given for 6 mo followed by 3-monthly maintenance pulses
- CYC was discontinued in pts with declining pulmonary function, adverse effects or static disease after 6 mo
- Average disease duration of 36 pts was 59.78 ± 63.22 mo
- 7 pts improved, 5 deteriorated, and 24 had stable disease
- Thus, 31 of 36 pts either improved or had static lung disease
- Mean FVC improved by 4.16% over 6 mo
- Mean DLCO improved by 5.66%
- Average % of predicted DLCO at baseline was 39%
Related Articles
Prognostic significance of S-phase kinase-associated protein 2 and p27kip1 in patients with diffuse large B-cell lymphoma: Effects of rituximab
Annals of Oncology, 11/10/09
Relevance Score: 64%
Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma
Leukemia and Lymphoma, 11/04/09
Relevance Score: 64%
Microscopic polyangiitis initiated with liver dysfunction, calf pain and fever of unknown origin
Rheumatology International, 10/08/09
Relevance Score: 64%
Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP
Medical Oncology, 10/06/09
Relevance Score: 62%
Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunosorbent assay
Rheumatology, 10/08/09
Relevance Score: 47%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Tadalafil for the treatment of pulmonary arterial hypertension
Expert Opinion in Pharmacotherapy, 12/14/09
Bosentan for chronic thromboembolic pulmonary hypertension
Expert Review of Cardiovascular Therapy , 12/14/09
Salmeterol/fluticasone propionate vs. double dose fluticasone propionate on lung function and asthma control in children
Pediatric Allergy and Immunology, 12/14/09
Today in Restrictive Lung Dz...keeping you current
Receive free subspecialty "5-minute updates" via email
Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease
European Respiratory Journal , 12/11/09
Pneumonia Recovery; Discrepancies in Perspectives of the Radiologist, Physician and Patient
Journal of General Internal Medicine, 12/11/09
Predictors of Body Mass Index in Patients With Moderate to Severe Emphysema
COPD: Journal of Chronic Obstructive Pulmonary Disease, 12/09/09
Sponsor
Article Search
Sponsor
Sponsor